our of achieving progress accomplishments here executing profitability, Thank you, and Rich, I and sialorrhea, team and and all well our developing continued our within been for are our candidate as business which on morning, chronic good the as toward at lead has look as to treatment fronts excessive drooling. referred advancing The NTXXXX, commonly everyone. development commercial pipeline highlighting to Neos forward we
sales ADHD reported products. our and for two Specifically, product net growth Cotempla net business, in X-ODT Adzenys revenue for and per pack we core XR-ODT. our
prescription year. quarter, in slightly we overall change is the last with consistent While late unveiled dipped strategy this volumes commercial this
quarter our net prescriptions in our driving As achieving row, reported continued and to in for in fifth a goal reflects that important to it’s which we quarterly gains focus of note continue productivity. we the toward reduction profitable generating our a operational on profitability, push loss,
using continuing monitoring analytics this has are Throughout data. analytics an in better Using these we refine we which enhance are real-time and our key three commercial of XXXX, our timely performance decisions more platform, and ongoing to on tactics. using informed commercial we information support enabled and been basis our performance Ultimately, and objectives. business assessing have
and our per third, share net incremental market pack. targeted base commercial to grow second, to of revenue prescriber increases prescription volumes, among First, achieve our to increase prescriptions in
key these Let to achieve doing performance are review what in success we me metrics.
within products our are We our focused base. target marketing prescriber effective on of
For pediatric we remained to on ages XX. Cotempla the patients of X its XR-ODT ADHD adolescent and between focused
ADHD which after patients. range Cotempla for reduction a in very one symptoms all full XX% hour hours, is XX a dosing clinical important response with demonstrated ADHD Our of lasting a a significant
But an sports ADHD of vast and a for of patients to medication duration for school XX activities. the effect, providing onset who other home target with our need a thus during particularly coverage hour sustained and both beyond efficacy work, day and
ADHD segment XR-ODT, For Adzenys will offered by the ADHD, the fastest-growing with believe on the Adzenys are where and physicians in adults resonate XR-ODT with particularly effective we we symptom market patients. focused management
objectives that ADHD specialists specific patients for have We we accounts and that can business. the territory efforts ADHD with as help base focused a our net more approximately profitable XX operating prescriber to many largest medications These potential on of possible. squarely where the are has are specialty under as generate we believe a ability force sales revenue
network to will insured Rx Neos the operates a to Additionally, This continue expand Neos co-pays regardless sponsored their plan. of and predictable offers we and all individual program pharmacies are and affordable, through Connect of patient access commercially patients network. best-in-class insurance
extensive Neos in from based they believe for what medications early their the research was prescribing their upon in healthcare Rx HCPs professionals most frustrations feedback created appropriate about referred and patients. XXXX Connect to to as be
is staff. leads patients HCP unpredictable core addressing for and well callbacks as pharmacy which as Too Neos additional Connect frustration, barriers. and the and and the to in to are at We or on complaints office variable designed resulting focus co-pay their three work hassle Rx HCP often widely medications not patient for their to available the
for an patients ADHD as possible our appropriate co-pay coverage provide stable many to intended receiving their of many remains patients hassles insured the the First, office staff frustrate and prevent as along possible eliminate the patients benefit as second, HCP medication. establish third, and from monthly as regardless of medicines, plan, that and from that their commercially all individual affordable insurance
and we Neos program this the and have brands that are customers response Rx our believe from very both both differentiates of Neos the seen the our encouraged value We truly we tremendous by and offers to network to to-date. our competition, Connect growth ADHD
the quarter, participating we expanded pharmacies number During Neos network. of substantially the Rx in the Connect
that grocery quarter excess of large representing customers chain, the the network regional there in with we network increase an expect addition of of continue the at end a store XXXX, the of November XXXX. Furthermore be a our third XXX% Also of of expansion XXX pharmacies expect since will and business. end the the support to we to
performance quarter. to now the specific this Turning commercial numbers
increase XR-ODT, revenue net year one over the per increase $XXX, pack XX% a XXXX. For same same $XXX, XR-ODT, was Adzenys quarter for the over net per Cotempla a XX% And in quarter revenue was ago. pack
to made market and to significant business shift strides channels in XXXX more have profitable This continued growth reflects the segments. we
the decision our a by at ADHD quarter to to of profitable target X% sales in the We IQVIA our prescriptions volume-based the aligning attribute to products, our long-term end Aggregate of support for commercial prescribers core strategy strategy to quarter decline compared by force as better revenue to third XXXX XXXX, of XXXX. same away this from growth move a reported and decreased growth.
and this part productivity to when in As increase announced our commercial late organization. objectives sales shift, our of of we the XXXX, force overall key our of reorganization one was commercial
meaningful improvements in very seen this to-date have We area.
XX% in sales while and than at Neos of reducing more ADHD For a XXXX, look prescriptions to same spend overall quarter of realized the one-third. third third per the time, we the XXXX, at marketing we total compared example, increase sales by have territory, when quarter
We of forward into continue grow there the to to potential these future is look that our reporting believe a progress. lot and products to
of than asset result to conditions our Parkinson's swallow tremendous development the condition of with mental turning to an address that candidate drooling sialorrhea, inability of chronic to such is believe a unmet sufficiently more saliva. the NTXXXX, Now where treatment palsy, with our a lead We patients a a and high development one-third neurological ALS disease, for pipeline. as potential excessive exhibit retardation as cerebral need
experience States patients with and associated report and X.X the in annual available treatment most side-effects they due on treatment-limiting patients an basis Approximately, dosing to that physicians million the currently only complex this condition regimens the treatments. for reserve severe United
clinical social stigma forced associated and meaningful suffer this results with many This often to too being in with patients too issues the condition.
specifically. of during my a range unguarded during moment take impact of Parkinson's focus pillow to outpourings face the sleep challenges to saliva embarrassing wetting patients from moments. excessive disease The in of Let’s mild the drooling on these
excessive dysphasia, which aspiration advanced could disease as it swallowing be in liquids of individual can one indicator and to drooling is pneumonia leading is causes an severity, important As Parkinson's of difficulty in as Parkinson's cause clinically known with advances to can lead of an aspiration with food a This serious patients. death and more pneumonia. the even on choke
believe we to selective these engages offers preclinical treatments. chemical the patients. available new antagonist entity glands that, on data, based relative promise compound option treatment salivary of This in new receptors a is a for NTXXXX receptor muscarinic and a the currently preferentially
elsewhere, likely with tolerability once regimen. also develop an commonly offer approved treatment and NTXXXX millions twice that requirements authorities by will important the dosed as if the treatments. patients and dosing improved to or currently We regulatory an more plan with that potential complex many available be new their believe for of formulation option the profile of and titration to a We NTXXXX, caregivers an acceptable daily both orally-administered to the seen is only in without U.S.
transformative are We quarter pilot the during we and PK are this work as advancing possible. track treatment first as potentially initiate rapidly to option XXXX, on of to committed
opportunity where opportunities with can focus disease that we products there our portfolio with seek our infrastructure a as neurological we the with to also leverage a believe disorders large existing to commercial of symptoms will acquisition CNS complement We marketed associated exacerbate currently existing burden. overall is address to on
with In future quarterly progress growth Neos momentum operating conclusion our this we loss believe Connect our revenue improvements ahead. pipeline, development XX% exciting a net Rx a and strong network, Neos in with has in bright continued quarter, year-over-year our
accomplished long-term the that We the us all proud am and I growth feel of makes strategy year. position team and has for commercial our last over well really corporate
would With like Rich. I I you over to that, to and turn the thank call
